It is noted that, similar to many epigenetic inhibitors (e.g., DOT1L or LSD1 inhibitors 25, 37, 38), compound 1 did not significantly inhibit proliferation of sensitive cancer cells during the first 2-3 days, while it showed potent activity upon incubation for more than 5 days (Figure S7). The gene discussed is DOT1L; the disease is cancer.